Incannex Healthcare Inc. has announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA). The U.S. Food and Drug Administration (FDA) previously granted IHL-42X Fast Track designation for treating OSA, intended to facilitate the development and expedite the review of therapies targeting serious conditions with unmet medical need.
The company cites strong Phase II efficacy data and encouraging patient-reported outcomes as positioning IHL-42X as one of the leading oral pharmacotherapy programs currently in development for obstructive sleep apnea. According to Incannex, the combination of these clinical strengths, operational advancement through the DReAMzz study, and FDA Fast Track designation supports this competitive positioning.
In parallel, Incannex has completed manufacturing activities for IHL-42X clinical trial supply and secured the required import and export permits to efficiently distribute clinical material as study sites become activated. A newly appointed distribution partner has been fully onboarded to support supply chain management and study logistics throughout the trial.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/pressreleases/26/05/g52564657/incannex-healthcare-officially-commences-dreamzz-clinical-study-for-ihl-42x-in-obstructive-sleep-a